Avita Medical
(ASX:AVH), a regenerative medicine company, has announced that its ReGenerCell device is now being trialled at two further London hospitals.
Avita is currently trialling a regenerative approach to healing diabetic foot ulcers – and says three hospitals are now enlisted in this trial. Also, up to 24 patients will tested over a 26-week period.
ReGenerCell works by using a patient’s own cells to close foot ulcers amongst diabetics.
The company says that diabetes costs the NHS £8.8 billion each year (or almost 10% of the NHS budget) – with 140 diabetic patients a week subject to amputations.
The company says this trial is expected to finish by early next year.
Avita posted a net loss of $8.8 million at 30 June 2016.